Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives
Authors
Keywords
-
Journal
SEMINARS IN LIVER DISEASE
Volume 41, Issue 03, Pages 263-276
Publisher
Georg Thieme Verlag KG
Online
2021-06-16
DOI
10.1055/s-0041-1730949
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pursuing efficacious systemic therapy for hepatocellular carcinoma
- (2021) Ann-Lii Cheng Nature Reviews Gastroenterology & Hepatology
- Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
- (2021) Chia-Lang Hsu et al. Liver Cancer
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
- (2020) L.-T. Chen et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
- (2020) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature
- (2020) Vivek Kumar et al. ONCOLOGIST
- IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
- (2020) Stephen P Hack et al. Future Oncology
- Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
- (2020) Ahmed Omar Kaseb et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
- (2020) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Learning from clinical trials of neoadjuvant checkpoint blockade
- (2020) Judith M. Versluis et al. NATURE MEDICINE
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-based therapies for hepatocellular carcinoma
- (2020) David J. Pinato et al. ONCOGENE
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Novel systemic therapy for hepatocellular carcinoma
- (2020) Yawen Dong et al. Hepatology International
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
- (2020) David M. Waterhouse et al. JOURNAL OF CLINICAL ONCOLOGY
- Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
- (2020) Chang Gon Kim et al. JOURNAL OF HEPATOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan
- (2020) Yih-Jyh Lin et al. PLoS One
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach
- (2020) Judith M Versluis et al. Journal for ImmunoTherapy of Cancer
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Abstract No. 526 CheckMate-9DX: phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
- (2019) M. Jimenez Exposito et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Toripalimab: First Global Approval
- (2019) Susan J. Keam DRUGS
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2
- (2019) J Knox et al. ANNALS OF ONCOLOGY
- Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study
- (2019) Xubiao Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Sequencing Identifies WNK2 as a Driver in hepatocellular carcinoma and a Risk Factor for Early Recurrence
- (2019) Shao-Lai Zhou et al. JOURNAL OF HEPATOLOGY
- Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
- (2019) Thomas Yau et al. JOURNAL OF HEPATOLOGY
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma
- (2019) Ahmed Omar Kaseb et al. Cancer Immunology Research
- Perioperative exercise capacity in chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy
- (2019) Masaki Kaibori et al. PLoS One
- Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A
- (2019) Beom-Hui Lee et al. World Journal of Surgical Oncology
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- (2019) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels
- (2018) Gang Huang et al. ANNALS OF SURGERY
- Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil
- (2018) Charles Herbaux et al. BLOOD
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
- (2018) Zheng Wang et al. CLINICAL CANCER RESEARCH
- Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial
- (2018) Qian Chen et al. GUT
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma
- (2018) Chetana Lim et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
- (2018) Jae Uk Chong et al. ANNALS OF SURGICAL ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
- (2018) Roser Pinyol et al. GUT
- Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
- (2018) Anthony W.H. Chan et al. JOURNAL OF HEPATOLOGY
- Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
- (2018) Julien Calderaro et al. JOURNAL OF HEPATOLOGY
- Multiple biopsy passes and the risk of complications of percutaneous liver biopsy
- (2017) Heng Chi et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients
- (2017) Jack P. Silva et al. JOURNAL OF SURGICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized clinical trial of chemoembolization plus radiofrequency ablationversuspartial hepatectomy for hepatocellular carcinoma within the Milan criteria
- (2016) H. Liu et al. BRITISH JOURNAL OF SURGERY
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)
- (2016) Ming-Chih Ho et al. Liver Cancer
- The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals
- (2016) Junjie Xu et al. EBioMedicine
- Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma
- (2015) Gang Huang et al. ANNALS OF SURGERY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
- (2015) Joong-Won Park et al. LIVER INTERNATIONAL
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma
- (2015) Do Seon Song WORLD JOURNAL OF GASTROENTEROLOGY
- Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy
- (2014) Hyung Soon Lee et al. ANNALS OF SURGICAL ONCOLOGY
- Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
- (2014) Kiwamu Okita et al. JOURNAL OF GASTROENTEROLOGY
- Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: A prospective randomized controlled trial
- (2014) Kaiyun Chen et al. JOURNAL OF HEPATOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers
- (2013) Guido Torzilli et al. ANNALS OF SURGERY
- Assessing Prognostic Significance of Preoperative Alpha-Fetoprotein in Hepatitis B-Associated Hepatocellular Carcinoma: Normal is not the New Normal
- (2013) Sima Blank et al. ANNALS OF SURGICAL ONCOLOGY
- Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma
- (2013) Ahmed O. Kaseb et al. CANCER
- Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study
- (2013) Jianhua Yin et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity
- (2013) Leibo Xu et al. JOURNAL OF HEPATOLOGY
- Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative Resection
- (2011) Li-Tzong Chen et al. ANNALS OF SURGERY
- Effect of vitamin K2 on the recurrence of hepatocellular carcinoma
- (2011) Haruhiko Yoshida et al. HEPATOLOGY
- Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial
- (2010) Leonard B. Seeff et al. Clinical Gastroenterology and Hepatology
- Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population
- (2008) Alessandro Cucchetti et al. ANNALS OF SURGICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now